Medical Oncology

Uzm. Dr. Ece Ulukal Karancı

Doctor and researcher Antalya Şehir Hastanesi Antalya
Breast Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionAntalya Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 3 publications · Model version —From source
  • Publications19 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-0930-1016ORCIDFrom source
  • Last synchronised5 November 2026 07:28https://antalyasehir.saglik.gov.tr/TR-1060338/doktorlarimiz.html#ece-ulukal-karancisaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

19 publications

  1. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-44980-w PMID 41888201 Open-access full textSource: OpenAlex

  2. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor–positive, HER-2–negative metastatic breast cancer: A real-world, multicenter, retrospective study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e24144 Source: OpenAlex

  3. The Prognostic Significance of the NOLUS Score in Patients with Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor Therapy

    Acta Medica Alanya, 2026

    DOI 10.30565/medalanya.1842660 Open-access full textSource: ORCID

  4. Prognostic impact of pathological complete response in hormone receptor–positive/HER2-negative breast cancer treated with neoadjuvant chemotherapy: a multicenter cohort study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-63952-8 Open-access full textSource: ORCID

  5. Does Social Media Use Associate with Vasomotor, Sexual, and Musculoskeletal Symptoms in Breast Cancer Survivors Receiving Endocrine Therapy?

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15124726 PMID 42355893 Open-access full textSource: ORCID

  6. Prediction of pathological complete response after neoadjuvant treatment in triple negative breast cancer: a single center experience

    Pamukkale Medical Journal, 2026

    DOI 10.31362/patd.1707522 Open-access full textSource: ORCID

  7. Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study

    Cancer Management and Research, 2026

    DOI 10.2147/cmar.s570548 PMID 41930183 Open-access full textSource: OpenAlex

  8. Abstract PS1-11-04: Her2-low expression is associated with inferior progression-free survival in hr-positive metastatic breast cancer treated with CDK4/6 inhibitors

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps1-11-04 Source: OpenAlex

  9. 560eP Early neutropenia does not predict survival in older patients treated with CDK4/6 inhibitors: A real-world analysis

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.107581 Open-access full textSource: OpenAlex

  10. Effect of "watch and wait" on fear of recurrence in rectal cancer: A multicenter cross-sectional study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.12116 Open-access full textSource: OpenAlex

View all 19 publications